← All sectors / The AI transformation
030 · Pharma manufacturing & CDMOs
Making the molecules
Curve position
Binding constraint
Regulator qualified capacity for new therapeutic modalities.
Why this sector sits at Orbit
We place pharma manufacturing and contract manufacturers (CDMOs) at Orbit. The industry is established and led by large companies, including Lonza, Samsung Biologics, Fujifilm and Thermo Fisher, which compete by building and filling capacity. In 2026 Samsung Biologics bought a former GSK plant in Maryland, Fujifilm opened a £400m expansion at Teesside, and Lonza kept investing about CHF 500m in a Swiss fill-finish plant.
Heavy spending on new plants could look like Flight. But it's established companies expanding, not newcomers piling in on a fresh story. We found no dated constraint easing that would justify Liftoff. We didn't check current multiples, so our confidence is medium.
Evidence of faster sector-wide revenue growth and expanding multiples would push us toward Flight.
Reviewed on a two month cycle. The position moves only when a dated, verifiable change in the binding constraint justifies it.
Heatmap / How this sector's stocks are moving
| Stock | Price | 1 Day | 1 Week | 1 Month | Year to date |
|---|---|---|---|---|---|
| $TMO | $706.16 | +1.12% | +0.29% | +7.55% | +21.87% |
| $WST | $408.78 | +0.44% | +1.27% | +9.70% | +48.57% |
| $MEDP | $656.77 | −1.01% | −5.18% | +8.94% | +16.94% |
| $CRL | $326.29 | −7.27% | −12.75% | +6.99% | +63.57% |
| Sector average | −1.68% | −4.09% | +8.29% | +37.74% |
Prices as of November 5, 2026. The sector's move is the equal-weighted average of these listed companies, a market proxy for context, not recommendations. See it on the full heatmap →
Sentiment / The mood in this sector's stocks
Since 2018, Pharma manufacturing & CDMOs has been rolling over from Euphoria 23 separate times. After those, its stocks beat their usual three months 12 times (52%), by a median of +0.7 points.
Confidence: low, a split like this is common by chance, so no edge is called.
AI is accelerating drug discovery, but a discovered molecule is worthless until it is manufactured at clinical and then commercial scale. Contract development and manufacturing organizations own that capacity, and demand for it is rising faster than new plants can be built.
Historical context: pharmaceutical companies spent two decades outsourcing manufacturing to focus capital on research, creating a specialist industry with long contracts and high switching costs. Regulatory qualification of a facility takes years, which makes existing approved capacity genuinely scarce.
The structural driver is a pipeline shift toward biologics, cell and gene therapies, and peptides, all of which require different, more complex manufacturing than small molecule pills. Capacity for these modalities is tight, and supply chain security rules are pushing production toward domestic and allied facilities.
The technology layer inside the plants is where AI lands: process optimization that raises yield in fermentation and purification, predictive maintenance on equipment where unplanned downtime costs enormous sums, computer vision inspection of fill finish lines, and batch record automation that shortens regulatory release cycles.
Adoption economics are compelling because pharmaceutical manufacturing runs at low utilization by other industries' standards and carries punishing quality costs. A few points of yield or a shortened changeover repays software quickly, and regulators increasingly accept continuous manufacturing approaches that AI makes controllable.
The beneficiaries include the contract manufacturers themselves, the equipment makers supplying bioreactors and fill finish lines, single use consumables suppliers with razor blade economics, and the manufacturing execution software vendors validated for regulated environments.
The value chain runs from process development through clinical supply to commercial manufacturing and packaging. Value concentrates in qualified capacity for hard modalities, anyone can make tablets; few can make a viral vector at scale under inspection.
The overlooked layer includes small cap consumables and single use technology suppliers, specialty packaging and cold chain providers, analytical testing labs serving the industry, and the engineering firms that design and validate plants.
Competitive dynamics are shifting with policy: biosecurity legislation and reshoring incentives are redirecting contracts away from certain geographies, benefiting Western and allied capacity holders regardless of cost competitiveness.
Risks: capacity gluts have happened before when everyone built at once; customer concentration is high, and losing a single commercial program can gut a facility's economics; regulatory findings can shut a plant; and clinical failures upstream remove demand with no notice.
What to watch: capacity utilization and expansion announcements, biosecurity and reshoring policy, commercial program wins, and consumables pull through as a leading indicator of production volumes. The research treats manufacturing as the physical bottleneck behind the discovery story.